GSK's vaccines outperform other groups, achieving 11% growth in Q2

GSK

After making a big bet on the field, GlaxoSmithKline ($GSK) continues to post gains in vaccines. In second-quarter results released Wednesday, the British pharma reported that its vax group notched the highest growth of the company’s three major units as it neared £1 billion for the quarter.

GSK vaccines grew 11% in the second quarter, besting pharmaceutical growth of 2% and consumer healthcare growth of 7%. In total, the unit reeled in £960 million ($1.26 billion) in Q2 and £1.84 billion ($2.47 billion) in the first half.

To get there, GSK’s vaccines needed standout performances in Europe and internationally to offset a U.S. decline of 2%. In an earnings statement, GSK attributed a portion of the U.S. slip to “adverse movement in the CDC stockpile.” In Europe, GSK’s vaccines grew 11% thanks to Bexsero boosts in private markets, among other factors. Elsewhere around the world, the pharma enjoyed a 20% increase in vax sales.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

The results follow first-quarter growth of 23% on a reported basis and 14% on a pro forma basis for vaccines, boosted during the period by former Novartis ($NVS) shots Menveo and Bexsero. And the upward trend is exactly what GSK execs want to see following the company’s massive asset swap with Novartis in which it traded away its oncology assets for the Swiss pharma’s vaccines stall.

With more than a year of integration behind it, GSK said “costs for these major restructuring programmes are expected to reduce significantly in 2017 with only residual charges thereafter.” Vaccines pitched in £270 worth of profit in the second quarter, good for a 28.1% core operating margin.

That's a far cry from those figures shortly after the deal's close last year, when GSK's vax group achieved £161 million in profit at a 12.1% operating margin. At the time, CEO Andrew Witty said the unit was impacted by a "higher than anticipated cost base" from the Novartis deal.

- here's the release

Related Articles:
GSK's vaccine operating profit, margin dive on Novartis fold-in
GSK's vax revenues jump in 2015 while profit, margin slip
GSK's vaccine unit sees revenue, profit jump in Q3

Read more on

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.